Shattuck Labs to Present at Piper Sandler Immunology Symposium

The biotech company will showcase its lead DR3 antagonist antibody candidate SL-325 at the upcoming virtual event.

Published on Feb. 8, 2026

Got story updates? Submit your updates here. ›

Shattuck Labs, a clinical-stage biotechnology company focused on developing treatments for inflammatory and immune-mediated diseases, announced that it will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026. The company's management team, including the CEO, CFO, and VP of Clinical Development, will present an overview of Shattuck's lead program, SL-325, a potentially first-in-class DR3 antagonist antibody.

Why it matters

Shattuck's SL-325 represents a novel approach to targeting the clinically validated DR3/TL1A pathway, which plays a key role in inflammatory and immune-mediated diseases like inflammatory bowel disease (IBD). The company's participation in this high-profile immunology symposium highlights the potential of SL-325 and Shattuck's broader pipeline as it advances its therapies through clinical development.

The details

SL-325 is a fully Fc-silenced humanized immunoglobin G monoclonal antibody designed to achieve a complete and durable blockade of the DR3/TL1A pathway. Shattuck's preclinical studies have demonstrated high-affinity binding and superior activity over TL1A antibodies, providing a data-driven rationale for targeting the DR3 receptor rather than its ligand, TL1A. SL-325 is currently being evaluated in a Phase 1 clinical trial.

  • The Piper Sandler Virtual Novel Targets in Immunology Symposium will take place on February 12-13, 2026.
  • Shattuck's fireside chat presentation is scheduled for February 12, 2026 at 2:00 PM ET.

The players

Shattuck Labs, Inc.

A clinical-stage biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases, with a focus on its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody.

Taylor Schreiber, M.D., Ph.D.

Chief Executive Officer of Shattuck Labs.

Andrew R. Neill

Chief Financial Officer of Shattuck Labs.

Michael Choi, M.D.

Vice President of Clinical Development at Shattuck Labs.

Got photos? Submit your photos here. ›

What’s next

A replay of the prerecorded presentation from the Piper Sandler Virtual Novel Targets in Immunology Symposium fireside chat will be available on the Events and Presentations section of Shattuck Labs' website starting at 2:00 PM ET on Thursday, February 12, 2026. The replay will be archived for up to 30 days following the presentation date.

The takeaway

Shattuck Labs' participation in the Piper Sandler Virtual Novel Targets in Immunology Symposium highlights the potential of its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody, as the company advances its pipeline of novel therapeutics targeting inflammatory and immune-mediated diseases.